Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma

Inclusion Criteria

• •Astma patients followed in the Respiratory Outpatient Ward, Hvidovre Hospital, Amager Hospital or Glostrup Hospital.
• •At least one of the following test suggestive for asthma, performed at any time during the outpatient course: 1) FEV1-reversibility on at least 12% and 200 ml after administration of bronchodilator or Prednisolon course, 2) positive bronchial provocation test, such as mannitol, 3) peakflow (PF)-variation of at least 20% assessed during a 14-day period, measured twice daily and at asthmatic symptoms, or 4) Variability in FEV1 on at least 12% and 200 ml
• •Age 18-65 years
• •Treated with ICS daily in doses equivalent to Budesonide 800 microg daily or more
• •ICS adherence of at least 80% during the last year, assessed from used prescriptions
• •Serum-periostin \< 50 ng/ml at screening (8)
• •FeNO \< 25 ppb at all prior visits
• •Blood-eosinophils \<0,15 at screening
• •Signed informed consent